This review reports the incidence of hyperprolactinemia, its relationship with genotype, and prolactin-related side effects in children and adolescents treated with antipsychotics.
Method:
Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine. Twenty-nine studies were selected after a literature search in the English Medline/Embase/Psychinfo/EBM databases (1965 to August, 2008).
Results:
All antipsychotics, except clozapine, ziprasidone, and quetiapine, increase the mean prolactin level from baseline values of 8.0 ng/mL to 25–28 ng/mL after 4 weeks of treatment (reference range 0–15 ng/mL). The most and best data are available for risperidone. Five risperidone studies (n = 577) show an increase of prolactin level from 7.8 ng/mL to 17.7 ng/mL after 1 year of treatment, and two risperidone studies (n = 60) show an increase from 7.4 ng/mL to 24.9 ng/mL after 2 years of treatment. Aggregated over all antipsychotics, prolactin-related side effects, such as gynecomastia, galactorrhea, irregular menses, and sexual dysfunction, were reported by 4.8% of the children and adolescents. No data are available on bone mineral density in relation to antipsychotic-induced hyperprolactinemia in children and adolescents. Prolactin levels may be influenced by the genetic differences that influence prolactin metabolism and D2 dopamine receptor density.
Conclusion:
Persistent elevation of prolactin for periods up to 2 years has been documented in maintenance treatment with risperidone. Very limited long-term data of pimozide, olanzapine, and quetiapine prohibit drawing conclusions for these antipsychotics. Systematic long-term observational studies, including specific questionnaires as well as physical examination, are needed to investigate prolactin-related side effects of antipsychotic treatment in children and adolescents.
Get full access to this article
View all access options for this article.
References
1.
AbrahamG, HalbreichU, FriedmanRH, JosiassenRC. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res, 59:17–18. 2003a.
2.
AbrahamG, PaingWW, KaminskiJ, JosephA, KohegyiE, JosiassenRC. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. Am J Psychiatry, 160:1618–1620. 2003b.
3.
AlfaroCL, WudarskyM, NicolsonR, GochmanP, SpornA, LenaneM. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol, 12:83–91. 2002.
4.
AmanMG, De SmedtG, DerivanA, LyonsB, FindlingRL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry, 159:1337–1346. 2002.
5.
AndersonGM, ScahillL, McCrackenJT, McDougleCJ, AmanMG, TierneyE. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry, 61:545–550. 2007.
6.
ArangoC, ParelladaM, MorenoDM. Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol, 14,Suppl 4:S471–S479. 2004.
7.
BeckerAL, EppersonCN. Female puberty: Clinical implications for the use of prolactin-modulating psychotropics. Child Adolesc Psychiatr Clin N Am, 15:207–220. 2006.
8.
BemboSA, CarlsonHE. Gynecomastia: Its features, and when and how to treat it. Cleve Clin J Med, 71:511–517. 2004.
9.
BevanJS. Interpreting prolactin levels: Implications for the management of large pituitary lesions. Br J Neurosurg, 5:3–6. 1991.
BobesJ, GarcAPMP, RejasJ, HernandezG, Garcia-GarciaM, Rico-VillademorosF. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. J Sex Marital Ther, 29:125–147. 2003.
ByerlyM, SuppesT, TranQV, BakerRA. Clinical implications of antipsychotic-induced hyperprolactinaemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives. J Clin Psychopharmacol, 27:639–661. 2007
14.
CarterDA, McGarrickGM, NortonKR, PaykelES, Prysor-JonesRA, WhiteheadSA. The effect of chronic neuroleptic treatment on gonadotrophin release. Psychoneuroendocrinology, 7:201–207. 1982.
15.
ColaoA, Di SommaC, LocheS, Di SarnoA, KlainM, PivonelloR. Prolactinomas in adolescents: Persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf ), 52:319–327. 2000.
16.
CooperWO, HicksonGB, FuchsC, ArbogastPG, RayWA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med, 158:753–759. 2004.
17.
CorrellCU. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry, 47:9–20. 2008a.
18.
CorrellCU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry,, 20:195–201. 2008b.
19.
CorrellCU, LeuchtS, KaneJM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry, 161:414–425. 2004.
20.
CostaAM, de LimaMS, FariaM, FilhoSR, de OliveiraIR, de Jesus MariJ. A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J Psychopharmacol, 21:165–170. 2007.
21.
CroonenberghsJ, FegertJM, FindlingRL, De SmedtG, Van DongenS. Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry, 44:64–72. 2005.
22.
DaviesJH, EvansBA, GregoryJW. Bone mass acquisition in healthy children. Arch Dis Child, 90:373–378. 2005.
23.
DittmannRW, MeyerE, FreislederFJ, RemschmidtH, Mehler-WexC, JunghanssJ. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: Results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol, 18:54–69. 2008.
24.
DolderCR, LacroJP, DunnLB, JesteDV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents?Am J Psychiatry, 159:103–108. 2002.
25.
DuvalF, GuillonMS, MokraniMC, CrocqMA, Garcia DuarteF. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder. Psychoneuroendocrinology, 33:255–259. 2008.
26.
FegertJM, FindlingRL, deSmedtG. Risperidon zur Behandlung aggressiv-impulsiven Verhaltens bei Kindern und Jugendlichen mit Intelligenz im unteren Durchschnittsbereich, Lernbehinderung und leichter geistiger Behinderung. [Risperidone in children and adolescents with disruptive behavior disorders, learning disorders and subaverage intelligence.] Nervenheilkunde, 22:93–97. 2003.
27.
FindlingRL, McNamaraNK. Atypical antipsychotics in the treatment of children and adolescents: Clinical applications. J Clin Psychiatry, 65,Suppl 6:30–4. 2004.
FrazierJA, MeyerMC, BiedermanJ, WozniakJ, WilensTE, SpencerTJ. Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry, 38:960–965. 1999.
30.
GässlerN, PeuschelT, PankauR. Pediatric reference values of estradiol, testosterone, lutropin, follitropin and prolactin. Clin Lab, 46:553–560. 2000.
31.
GreenspanSL, NeerRM, RidgwayEC, KlibanskiA. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med, 104:777–782. 1986.
32.
GreenspanSL, OppenheimDS, KlibanskiA. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med, 110:526–531. 1989.
33.
HaddadPM, WieckA. Antipsychotic-induced hyperprolactinaemia: Mechanisms: Mechanisms, clinical features and management.”Drugs, 64:2291–2314. 2004.
34.
HalbreichU, KinonBJ, GilmoreJA, KahnLS. Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects. Psychoneuroendocrinology, 28,Suppl 1:53–67. 2003.
35.
HanavadiS, BanerjeeD, MonypennyIJ, ManselRE. The role of tamoxifen in the management of gynaecomastia. Breast, 15:276–280. 2006.
36.
HardanA, JohnsonK, JohnsonC, HrecznyjB. Case study: Risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry, 35:1551–1556. 1996.
37.
HedigerML, EnglandLJ, MolloyCA, YuKF, Manning-CourtneyP, MillsJL. Reduced bone cortical thickness in boys with autism or autism spectrum disorders. J Autism Dev Disord, 38:848–856. 2008.
38.
HellingsJA, ZarconeJR, ValdovinosMG, ReeseRM, GaughanE, SchroederSR. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol, 15:885–892. 2005.
39.
HowardL, KirkwoodG, LeeseM. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry, 190:129–134. 2007.
40.
HowlettTA, WassJA, GrossmanA, PlowmanPN, CharlesworthM, TouzelR. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: Response to medical therapy. Clin Endocrinol (Oxf ), 30:131–140. 1989.
KawanoY, KamihigashiS, NakamuraS, MiyakawaI. Delayed puberty associated with hyperprolactinemia caused by pituitary microadenoma. Arch Gynecol Obstet, 264:90–92. 2000.
43.
KnegteringH. Antipsychotic treatment, sexual functioning: Role of prolactin. Rijksuniversiteit Groningen. Groningen, Rijksuniversiteit Groningen. Doctor, 169. 2003.
44.
KnegteringH, van der MoolenAE, CasteleinS, KluiterH, van den BoschRJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?Psychoneuro-endocrinology, 28,Suppl 2:109–123. 2003.
45.
KnegteringR, CasteleinS, BousH, Van Der LindeJ, BruggemanR, KluiterH. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol, 24:56–61. 2004.
46.
KnegteringH, BoksM, BlijdC, CasteleinS, van den BoschRJ, WiersmaD. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther, 32:315–326. 2006.
47.
LangerG, SacharEJ, HalpernFS, GruenPH, SolomonM. The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: Neuroendocrine studies in normal men. J Clin Endocrinol Metab, 45:996–1002. 1977.
48.
LentonEA, BrookLM, SobowaleO, CookeID. Prolactin concentrations in normal menstrual cycles and conception cycles. Clin Endocrinol (Oxf ), 10:383–391. 1979.
49.
LubyJ, MrakotskyC, StaletsMM, BeldenA, HeffelfingerA, WilliamsM. Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopharmacol, 16:575–587. 2006.
50.
MaloneRP, MaislinG, ChoudhuryMS, GiffordC, DelaneyMA. Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry, 41:140–147. 2002.
51.
MaloneRP, DelanyMA, HymanSB, CaterJR. Ziprasidone in adolescents with autism: An open-label pilot study. J Child Adolesc Psychopharmacol, 17:779–790. 2007.
MasiG, CosenzaA, MucciM. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol, 11:389–394. 2001.
54.
MasiG, CosenzaA, MucciM, BrovedaniP. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry, 64:1039–1047. 2003.
55.
McConvilleBJ, ArvanitisLA, ThyrumPT, YehC, WilkinsonLA, ChaneyRO. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry, 61:252–260. 2000.
56.
McCrackenJT, McGoughJ, ShahB, CroninP, HongD, AmanMG. Risperidone in children with autism and serious behavioral problems. N Engl J Med, 347:314–321. 2002.
57.
MeaneyAM, O'KeaneV. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication. J Psychopharmacol, 17:455–458. 2003.
58.
MeaneyAM, SmithS, HowesOD, O'BrienM, MurrayRM, O'KeaneV. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry, 184:503–508. 2004.
59.
MeaneyAM, O'KeaneV. Bone mineral density changes over a year in young females with schizophrenia: Relationship to medication and endocrine variables. Schizophr Res, 93:136–143. 2007.
60.
MenzinJ, BoulangerL, FriedmanM, MackellJ, LloydJR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv, 54:719–723. 2003.
61.
MisraM, PapakostasGI, KlibanskiA. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry, 65:1607–1618quiz 1590, 1760–1761, 2004.
62.
MolitchME. Medication-induced hyperprolactinemia. Mayo Clin Proc, 80:1050–1057. 2005.
63.
NakoneznyPA, ByerlyMJ, RushAJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther, 33:203–216. 2007
64.
O'KeaneV, MeaneyAM. Antipsychotic drugs: A new risk factor for osteoporosis in young women with schizophrenia?J Clin Psychopharmacol, 25:26–31. 2005.
65.
PappagalloM, SilvaR. The effects of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol, 14:359–371. 2004.
66.
PapparigopoulosT, LiappasJ, TzavellasE, MourikisI, SoldatosC. Amisulpiride-induced hyperprolactinaemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry, 31:92–96. 2007.
67.
PattonML, WoolfPD. Hyperprolactinemia and delayed puberty: A report of three cases and their response to therapy. Pediatrics, 71:572–575. 1983.
68.
ReyesM, CroonenberghsJ, AugustynsI, EerdekensM. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol, 16:260–272. 2006.
69.
SackJ, FriedmanE, TadmorR, SaharA, KatznelsonD. Growth and puberty arrest due to prolactinoma. Acta Paediatr Scand, 73:863–867. 1984.
70.
SaitoE, CorrellCU, GallelliK, McMenimanM, ParikhUH, MalhotraAK. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol, 14:350–358. 2004.
71.
SalleeFR, DoughertyD, SethuramanG, VrindavanamN. Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biol Psychiatry, 40:1044–1050. 1996.
72.
SchirmE, TobiH, ZitoJM, de Jong-van den BergLT. Psychotropic medication in children: A study from the Netherlands. Pediatrics, 108:E25. 2001.
73.
SeemanP, BzowejNH, GuanHC, BergeronC, BeckerLE, ReynoldsGP. Human brain dopamine receptors in children and aging adults. Synapse, 1:399–404. 1987.
74.
ShawJA, LewisJE, PascalS, SharmaRK, RodriguezRA, GuillenR. A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol, 11:415–424. 2001.
75.
SikichL, HamerRM, BashfordRA, SheitmanBB, LiebermanJA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology, 29:133–145. 2004.
76.
SimeonJ, LawrenceS, SimeonS. Effects of pimozide on prolactin in children [proceedings]Psychopharmacol Bull, 15:40–42. 1979.
77.
SirisSG, SirisES, van KammenDP, DochertyJP, AlexanderPE, BunneyWE. Effects of dopamine blockade on gonadotropins and testosterone in men. Am J Psychiatry, 137:211–214. 1980.
78.
SnyderR, TurgayA, AmanM, BinderC, FismanS, CarrollA. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry, 41:1026–1036. 2002.
79.
StallerJ. The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol, 16:317–326. 2006.
80.
StevensJR, KymissisPI, BakerAJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol, 15:893–900. 2005.
81.
SuwaS, NaruseH, OhuraT, TsuruharaT, TakesadaM, YamazakiK. Influence of pimozide on hypothalamo-pituitary function in children with behavioral disorders. Psychoneuroendocrinology, 9:37–44. 1984.
82.
TroostPW, LahuisBE, HermansMH, BuitelaarJK, van EngelandH, ScahillL. Prolactin release in children treated with risperidone: Impact and role of CYP2D6 metabolism. J Clin Psychopharmacol, 27:52–57. 2007.
83.
TurgayA, BinderC, SnyderR, FismanS. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics, 110:e34. 2002.
84.
WoodsSW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry, 64:663–667. 2003.
85.
WudarskyM, NicolsonR, HamburgerSD, SpechlerL, GochmanP, BedwellJ. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol, 9:239–245. 1999.
86.
ZitoJM, SaferDJ, DosReisS, GardnerJF, MagderL, SoekenK. Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med, 157:17–25. 2003.
